

acg2usa.ST25



00270

PATENT TRADEMARK OFFICE

## SEQUENCE LISTING

9  
<110> Gevas, Philip  
Grimes, Stephen  
Karr, Stephen  
Michaeli, Dov  
Watson, Susan

&lt;120&gt; Prevention and Treatment of Hypergastrinemia

&lt;130&gt; ACG2USA

&lt;140&gt; US 09/700,329

&lt;141&gt; 2001-02-08

&lt;150&gt; PCT/US99/10751

&lt;151&gt; 1999-05-14

&lt;150&gt; 60/085,714

&lt;151&gt; 1998-05-15

&lt;160&gt; 9

&lt;170&gt; PatentIn version 3.0

&lt;210&gt; 1

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; human gastrin peptide

&lt;220&gt;

&lt;221&gt; MOD\_RES

&lt;222&gt; (1)..(1)

&lt;223&gt; pyroglutamic acid

&lt;400&gt; 1

Glu Gly Pro Trp Leu Glu Glu Glu Glu  
1 5

&lt;210&gt; 2

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; human gastrin peptide

&lt;220&gt;

&lt;221&gt; MOD\_RES

&lt;222&gt; (1)..(1)

&lt;223&gt; pyroglutamic acid

&lt;400&gt; 2

Glu Leu Gly Pro Gln Gly Arg Pro Pro Pro Pro Cys  
1 5 10

<210> 3  
<211> 7  
<212> PRT  
<213> human or synthetic peptide

<400> 3

Ser Ser Pro Pro Pro Pro Cys  
1 5

<210> 4  
<211> 7  
<212> PRT  
<213> human gastrin peptide

<220>  
<221> MOD\_RES  
<222> (7)..(7)  
<223> AMIDATION

<400> 4

Glu Ala Tyr Gly Trp Met Asp  
1 5

<210> 5  
<211> 12  
<212> PRT  
<213> human gastrin peptide

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> pyroglutamic acid

<400> 5

Glu Gly Pro Trp Leu Glu Arg Pro Pro Pro Pro Cys  
1 5 10

<210> 6  
<211> 11  
<212> PRT  
<213> human gastrin peptide

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> pyroglutamic acid

<400> 6

Glu Gly Pro Trp Leu Arg Pro Pro Pro Pro Cys  
1 5 10

acg2usa.ST25

<210> 7  
<211> 10  
<212> PRT  
<213> human gastrin peptide

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> pyroglutamic acid

<400> 7

Glu Gly Pro Trp Arg Pro Pro Pro Pro Cys  
1 5 10

<210> 8  
<211> 12  
<212> PRT  
<213> rat gastrin peptide

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> pyroglutamic acid

<400> 8

Glu Arg Pro Pro Leu Glu Arg Pro Pro Pro Pro Cys  
1 5 10

<210> 9  
<211> 15  
<212> PRT  
<213> human gastrin peptide

<400> 9

Asp Pro Ser Lys Lys Gln Gly Pro Trp Leu Pro Pro Pro Pro Cys  
1 5 10 15



00270

PATENT TRADEMARK OFFICE

Exhibit A

COPY

## PATENT

Serial No. \_\_\_\_\_ Doc. No. 00270 Atty/Sec. MKS/ldh Date 11-14-00Inventor J. Gervais et al. Client ACC.Title Prevention and Treatment of Hypergastrinemia

The following has been received in the U.S. Patent and Trademark Office on the date stamped hereon:

☒ 22 pp. Spec., 24 Claims, 1 pg. Abstract ☐ pp. Amendment: OA dtd \_\_\_\_\_☒ 3 pp. Declaration/Power of Attorney ☐ pp. Response: OA dtd \_\_\_\_\_☒ 1 pp. Verified Statement (Small Entry) ☒ 2 pp. Transmittal Letter☐ shts. Informal Drawings ☐ Issue Fee☒ 12 shts. Formal Drawings (Figs. 1-12) ☐ Notice of Appeal & Fee☐ pp. Assignment ☒ Check # 15703 for \$ 345.00☒ 2 pp. Preliminary Amendment ☒ Check # 7504 for \$ 90.00☐ pp. Extension of Time ☒ 7 pg. Second Prel. Am.☐ pp. Information Disclosure Statement ☒ 1 pg. Transmittal Letterwith PTO-1449 and \_\_\_\_\_ references ☒ 3 pg. Sec. List ☒ 1 pg. Statement

The Patent and Trademark Office is respectfully requested to place its stamp on this postal card and place

it in the outgoing mail. ☒ Copy of Receipt for Sec. List

Respectfully,

HOWSON AND HOWSON

Express Mail 120

EX 990703206US

MEYS

09/700329

525 Rec'd PCT/PTO 14 NOV 2000

acg2usa.ST25

*copies*  
**Exhibit B**

## SEQUENCE LISTING

**COPY**

<110> Gevas, Philip  
Grimes, Stephen  
Karr, Stephen  
Michaeli, Dov  
Watson, Susan

<120> Prevention and Treatment of Hypergastrinemia

<130> ACG2USA

<150> PCT/US99/10751

<151> 1999-05-14

<150> 60/085,714

<151> 1998-05-15

<160> 9

<170> PatentIn version 3.0

<210> 1

<211> 9

<212> PRT

<213> human

<220>

<221> MOD\_RES

<222> (1)..(1)

<223> pyroglutamic acid

<400> 1

Glu Gly Pro Trp Leu Glu Glu Glu Glu  
1 5

<210> 2

<211> 12

<212> PRT

<213> human

<220>

<221> MOD\_RES

<222> (1)..(1)

<223> pyroglutamic acid

<400> 2



acg2usa.ST25

Glu Leu Gly Pro Gln Gly Arg Pro Pro Pro Pro Cys  
1 5 10

<210> 3  
<211> 7  
<212> PRT  
<213> human or synthetic peptide

<400> 3

Ser Ser Pro Pro Pro Pro Cys  
1 5

<210> 4  
<211> 7  
<212> PRT  
<213> human or synthetic peptide

<220>  
<221> MOD\_RES  
<222> (7)..(7)  
<223> AMIDATION

<400> 4

Glu Ala Tyr Gly Trp Met Asp  
1 5

<210> 5  
<211> 12  
<212> PRT  
<213> human

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> pyroglutamic acid

<400> 5

Glu Gly Pro Trp Leu Glu Arg Pro Pro Pro Pro Cys  
1 5 10

<210> 6  
<211> 11  
<212> PRT  
<213> human

<220>

acg2usa.ST25

<221> MOD\_RES  
 <222> (1)..(1)  
 <223> pyroglutamic acid

<400> 6

Glu Gly Pro Trp Leu Arg Pro Pro Pro Pro Cys  
 1 " 5 10

<210> 7  
 <211> 10  
 <212> PRT  
 <213> human

<220>  
 <221> MOD\_RES  
 <222> (1)..(1)  
 <223> pyroglutamic acid

<400> 7

Glu Gly Pro Trp Arg Pro Pro Pro Pro Cys  
 1 5 10

<210> 8  
 <211> 12  
 <212> PRT  
 <213> rat

<220>  
 <221> MOD\_RES  
 <222> (1)..(1)  
 <223> pyroglutamic acid

<400> 8

Glu Arg Pro Pro Leu Glu Arg Pro Pro Pro Pro Cys  
 1 5 10

<210> 9  
 <211> 15  
 <212> PRT  
 <213> human

<400> 9

Asp Pro Ser Lys Lys Gln Gly Pro Trp Leu Pro Pro Pro Pro Cys  
 1 5 10 15